Zum Inhalt

M. Sibilia et al. (eds). Drugs for HER-2-positive breast cancer. Milestones in drug therapy. © Springer Basel AG 2011

  • 01.08.2012
  • Book Review
Erschienen in:

Auszug

Identification of HER-2 as a molecular target in a subset of breast cancer patients has transformed the treatment approach and improved outcomes in this group. The notion that HER-2 positivity is a negative prognostic marker has been strongly challenged in recent years with the introduction of effective anti-HER-2 therapies. Better understanding of interwoven EGFR/ErbB signalling pathways has led to better targeting. …
Titel
M. Sibilia et al. (eds). Drugs for HER-2-positive breast cancer. Milestones in drug therapy. © Springer Basel AG 2011
Verfasst von
S. W. Wong
R. M. Lowenthal
Publikationsdatum
01.08.2012
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammopharmacology / Ausgabe 4/2012
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-012-0129-5